Damora Therapeutics (DMRA) Cash from Financing Activities (2020 - 2026)
Damora Therapeutics' (DMRA) quarterly Cash from Financing Activities came in at $295.9 million in Q1 2026, up 172953.22% on a QoQ basis from $171000.0 in Q3 2023.
Damora Therapeutics (DMRA) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 4 years of Cash from Financing Activities data on file, last reported at $295.9 million in Q1 2026.
- Quarterly Cash from Financing Activities changed N/A year-over-year to $295.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $298.8 million (changed N/A YoY) and the FY2025 annual result came in at $266.8 million, changed N/A from the prior year.
- Cash from Financing Activities improved to $295.9 million in Q1 2026, from $171000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $295.9 million in Q1 2026 to a low of $23000.0 in Q1 2023.
- A 3-year average of $49.9 million and a median of $297500.0 in 2022 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 59.67% in 2023, down 59.67% in 2023.
- Tracing DMRA's Cash from Financing Activities over 3 years: stood at $65000.0 in 2022, then jumped by 163.08% to $171000.0 in 2023, then soared by 172953.22% to $295.9 million in 2026.
- The last three Cash from Financing Activities figures came in at $295.9 million (Q1 2026), $171000.0 (Q3 2023), and $2.7 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | 29.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.51 Mn |
| Jun 30, 2026 | 29.51 Mn |
| Mar 31, 2026 | 295.92 Mn |
| Mar 31, 2026 | 295.92 Mn |
| Sep 30, 2023 | 171,000.00 |
| Sep 30, 2023 | 171,000.00 |
| Jun 30, 2023 | 2.68 Mn |
| Jun 30, 2023 | 2.68 Mn |
| Mar 31, 2023 | 23,000.00 |
| Mar 31, 2023 | 23,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Dec 31, 2022 | 65,000.00 |
| Sep 30, 2022 | 424,000.00 |
| Sep 30, 2022 | 424,000.00 |
| Dec 31, 2020 | 91.79 Mn |
| Dec 31, 2020 | 91.79 Mn |
| Sep 30, 2020 | 55.93 Mn |
| Sep 30, 2020 | 55.93 Mn |
| Jun 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 1,000.00 |